Sector Expert: Ram Selvaraju

Rodman & Renshaw

Image: Ram Selvaraju

Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg."



Recent Interviews

Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw (2/10/16)
pulseofdollar630

It takes nerves of steel to follow micro-cap stocks and ascribe future valuations in hefty multiples. Raghuram "Ram" Selvaraju of Rodman & Renshaw has made the micro- and small-cap biotech universe his specialty, and his track record is impressive. In this interview with The Life Sciences Report, Selvaraju, a former big pharma researcher, details four growth names that could follow in the hallowed footsteps of previous winners.

Immunotherapy Inside the Cell: Three Companies on Their Way to the 'Holy Grail' of Cancer Treatment (1/6/16)
Sorrento Drug Targets

Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologiesŚand the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc.Świth Lin, Followwill and Ram Selvaraju of Rodman and Renshaw.

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist (12/15/15)
2016_watchlist_newsletter_graphic_large.2

In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.

Recent Quotes

"INO has sufficient capital to finish the study, and management expects to report results from the Phase 1 trial by the end of 2016."

— Ram Selvaraju, H.C. Wainwright & Co. (6/21/16)
moreá>

"INO is on track to commence the VGX-3100 Phase 3 study in 2016; we reiterate our Buy rating."

— Ram Selvaraju, H.C. Wainwright & Co. (5/10/16)
moreá>

"We expect positive readouts from DRRX's DUR-928 and the POSIMIR studies."

— Ram Selvaraju, Rodman & Renshaw (5/9/16)
moreá>

"We are initiating coverage on DRRX with a Buy rating."

— Ram Selvaraju, Rodman & Renshaw (4/25/16)
moreá>

"INO expects to initiate human trials of its Zika virus vaccine by the end of 2016."

— Ram Selvaraju, H.C. Wainwright & Co. (4/8/16)
moreá>

"INO's cervical dysplasia Phase 3 trial is to initiate in early Q3/16."

— Ram Selvaraju, H.C. Wainwright & Co. (3/16/16)
moreá>

"CYP signed an agreement with Regience to co-commercialize Cymerus."

— Ram Selvaraju, Rodman & Renshaw (3/4/16)
moreá>

"The Neutrolin platform positions CRMD particularly well going forward."

The Life Sciences Interview with Ram Selvaraju (2/10/16)
moreá>

more comments

"CYP has the only truly sustainable production platform for MSCs."

The Life Sciences Interview with Ram Selvaraju (2/10/16)
moreá>

"ATHX is getting a $15M upfront cash payment as part of its agreement with Tokyo-based big pharma Healios."

The Life Sciences Interview with Ram Selvaraju (2/10/16)
moreá>

"CYP received favorable clinical testing advice from the MHRA."

— Ram Selvaraju, Rodman & Renshaw (1/28/16)
moreá>

"CRMD has one of the few programs that deals conclusively with multidrug-resistant bacterial infections."

The Life Sciences Report Interview with Ram Selvaraju (1/27/16)
moreá>

"We should see SRNE's first investigational new drug (IND) application filed in 2016; there is enough evidence for investors to be intrigued."

The Life Sciences Report Interview with Ram Selvaraju (1/6/16)
moreá>

"INO generated very positive and encouraging clinical data from a Phase 2b trial of VGX-3100."

The Life Sciences Report Interview with Ram Selvaraju (1/6/16)
moreá>

"CRMD currently trades at a significant discount to peer publicly traded, single-product, anti-infective firms."

The Life Sciences Report Interview with Ram Selvaraju (12/15/15)
moreá>

"We initiate coverage of CYP with a Buy rating."

— Ram Selvaraju, Rodman & Renshaw (12/7/15)
moreá>

"We are initiating coverage of CRMD with a Buy rating."

— Ram Selvaraju, H.C. Wainwright & Co. (11/12/15)
moreá>

"We continue to anticipate approval of OMER's Omidira in the EU."

— Ram Selvaraju, MLV & Co (6/18/15)
moreá>

"Sales of OMER's lead marketed agent, Omidria, were $238K in Q1/15."

— Ram Selvaraju, MLV & Co (5/11/15)
moreá>

"OMER could achieve cash-flow-positive status in late 2015."

— Ram Selvaraju, MLV & Co (3/13/15)
moreá>

"INO will target product development within infectious disease."

— Ram Selvaraju, Aegis Capital (10/21/14)
moreá>

"The first patient was treated in CUR's Phase 1 NSI-566 trial."

— Ram Selvaraju, Aegis Capital (10/9/14)
moreá>

"CE marking allows CGIX's FHACT to be sold freely within the European Economic Area."

— Ram Selvaraju, Aegis Capital (9/3/14)
moreá>

"CGIX has sufficient capital to fund operations to break even status."

— Ram Selvaraju, Aegis Capital (8/14/14)
moreá>

"ARNI's onapristone could potentially be a suprabillion-dollar drug upon approval."

The Life Sciences Report Interview with Raghuram Selvaraju (8/13/14)
moreá>

"CUR has two very credible shots on goal."

The Life Sciences Report Interview with Raghuram Selvaraju (8/13/14)
moreá>

"INO has demonstrated that it is the preeminent DNA-based immunotherapy company."

— Ram Selvaraju, Aegis Capital (8/11/14)
moreá>

"CUR delivered an in line Q2/14, ending the period with $30.2M in cash."

— Ram Selvaraju, Aegis Capital (8/8/14)
moreá>

"NBS's AMR-001 Phase 2 study could pave the way for a transformative licensing agreement."

— Ram Selvaraju, Aegis Capital (8/8/14)
moreá>

"The final patient has been treated in CUR's Phase 2 NSI-566 study."

— Ram Selvaraju, Aegis Capital (8/4/14)
moreá>

"INO's trial met its primary endpoint with robust statistical significance."

— Ram Selvaraju, Aegis Capital (7/24/14)
moreá>

"CUR presented favorable safety and efficacy data on NSI-189."

— Ram Selvaraju, Aegis Capital (6/25/14)
moreá>

fewer comments


Due to permission requirements, not all quotes are shown.